Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo covers the month of May 2004, with the report dated May 21, 2004. The filing primarily addresses a corporate transaction involving an amendment to an agreement with Aventis regarding liquidity provisions for Aventis stock options.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a disclosure of a specific contractual amendment rather than a financial results statement.
Material Changes
On May 19, 2004, Sanofi-Synthelabo and Aventis entered into an Amendment Agreement. This agreement amends and replaces Schedule 1 (Liquidity for Aventis stock-options) of the original Agreement dated April 25, 2004, between the two entities.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or general business risks. The document notes that this report is incorporated by reference into Sanofi-Synthelabo's Registration Statement on Form F-4 (Registration No. 333-112314), which was declared effective on May 13, 2004.
Investor Verification Points
- Review the attached Exhibit 99.1 (Amendment Agreement) to understand the specific changes to the liquidity provisions for Aventis stock options.
- Verify the status of the broader merger or transaction context between Sanofi-Synthelabo and Aventis referenced in the Form F-4 Registration Statement.
- Confirm that no other material financial data was omitted from this specific 6-K filing, as it focuses solely on the Schedule 1 amendment.